Drugs / HS-20117
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07414953 | Mar 2026 → Apr 2027 expected | lung cancer | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06963502 | May 2025 → Dec 2028 expected | colorectal cancer, non-small cell lung carcinoma | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06621563 | Dec 2024 → Mar 2026 overdue | colorectal cancer, non-small cell lung carcinoma | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 1 | NCT05940116 | Jul 2023 → Jul 2025 overdue | non-small cell lung carcinoma | Hansoh BioMedical R&D Company | Not yet recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06417008 | May 2024 → Jun 2026 overdue | non-small cell lung carcinoma | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-20117 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07414953 ↗ |
| Modality | Monoclonal antibody | “fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody” NCT06417008 ↗ |
| Route | Intravenous | “receive IV infusion of HS-20117” NCT05940116 ↗ |
| Target | EGFR | “HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody.” NCT05940116 ↗ |
| Target | MET | “HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody.” NCT05940116 ↗ |